Genome-wide methylation data improves dissection of the effect of smoking on body mass index.

Authors

Carmen Amador (1)*, Yanni Zeng (1,2), Michael Barber (1), Rosie Walker (3,4), Archie Campbell (3), Andrew M. McIntosh (5), Kathryn L. Evans (3), David Porteous (3), Caroline Hayward (1), James F. Wilson (1,6), Pau Navarro (1), Chris S. Haley (1,7)

* Corresponding author

1 MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

2 Faculty of Forensic Medicine, Zhongshan School of Medicine, Sun Yat-Sen University, China

3 Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

4 Centre for Clinical Brain Sciences, Chancellor's Building, 49 Little France Crescent, Edinburgh BioQuarter, Edinburgh, UK

5 Division of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom

6 Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, UK

7 Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK

Abstract

Variation in obesity-related traits has a genetic basis with heritabilities between 40 and 70%. While the global obesity pandemic is usually associated with environmental changes related to lifestyle and socioeconomic changes, most genetic studies do not include all relevant environmental covariates, so genetic contribution to variation in obesity-related traits cannot be accurately assessed. Some studies have described interactions between a few individual genes linked to obesity and environmental variables but there is no agreement on their total contribution to differences between individuals. Here we compared self-reported smoking data and a methylation-based proxy to explore the effect of smoking and genome-by-smoking interactions on obesity related traits from a genome-wide perspective to estimate the amount of variance they explain . Our results indicate that exploiting omic measures can improve models for complex traits such as obesity and can be used as a substitute for, or jointly with, environmental records to better understand causes of disease.

Introduction

Variation in obesity-related traits such as body mass index (BMI) has a complex basis with heritabilities ranging from 40 to 70%, with the genetic variants detected to date explaining up to 5% of BMI variation[1]. In addition to genetics, studies suggest that the increase in obesity prevalence in recent decades is linked to environmental causes, such as dietary changes and a more sedentary lifestyle[2,3,4,5]. The fact that all relevant environmental effects have not been accounted for in genetic studies has potentially reduced GWAS power to detect susceptibility variants. On top of this, several studies suggest that gene-by-environment interactions also play an important role in obesity and other complex traits [2,6,7,8,9,10] and many researchers are focusing on finding interactions between specific genes and certain environments. Genotype-by-age interactions and genotype-by-sex interactions have also been detected for several health-related traits[10,11,12]. Recently, when performing GWAS on traits like BMI, lipids, and blood pressure, several studies have stratified their samples on the basis of smoking status or have explicitly modelled interactions leading to identification of new genetic variants associated with those traits [13,14,15]. Some studies have attempted to quantify the overall contribution of genetic interactions with smoking. Robinson, et al.[12] estimated them to explain around 4% of BMI variation in a subset of unrelated UK Biobank samples. In contrast, also in UK Biobank, using a new approach that only requires summary statistics, Shin & Lee[17] estimated the contributions of the interactions to be much smaller: 0.6% of BMI variation.

In this study, we aim to estimate the contribution of smoking and its interaction with genetic variation to obesity variation , using self-reported measures of smoking and a methylomic proxy of smoking exposure. We hypothesised that use of a proxy, rather than self-reported smoking, and fitting gene by smoking interactions would lead to more a more accurate model. DNA methylation is an epigenetic mark that can be affected by genetics and environmental exposures[18,19,20,21,22,23]. Variation in methylation is correlated with gene expression, plays a crucial role in development, in maintaining genomic stability[24,25,26], and has been associated with disease[27,28,29,30,31] and aging[32,33]. Epigenome-wide

56 association analyses (EWAS) have identified multiple associations between DNA methylation levels at
57 specific genomic locations and smoking[19,34,35,36]. These so-called *signatures* of smoking in the epigenome
58 can help discriminate the smoking status of the individuals in a cohort[20], and, if sufficiently accurate,
59 could be an improvement on self-reported measures, by adding information not captured (accurately)
60 in the self-reported measure, such as passive smoking or real quantity of tobacco smoked.

61 Here, we aim to estimate the contribution to obesity variation of smoking and its interaction with
62 genetic variation in two different cohorts, using self-reported measures of smoking and a methylomic
63 proxy for smoking. Thus, we measured the contribution of smoking-associated methylation signatures
64 and genome-by-methylation interactions to trait variation. We performed analyses in both sexes jointly
65 and independently and also including genome-by-smoking-by-sex interactions, and we showed that
66 omics data can be exploited as proxies for environmental exposures to improve our understanding of
67 complex trait architecture. We observed that using an appropriate set of CpG sites, methylation can be
68 used to model trait variation associated with smoking, and genome-by-smoking interactions suggesting
69 potential applications for better prediction and prognosis of complex disease and expanding these
70 modelling approaches to other environments and traits.

71 Results

72 The aim of this work was to explore the influence of smoking and genome-by-smoking interactions on
73 trait variation, modelling them from self-reported information and using DNA methylation in both sexes
74 jointly and separately. We used a variance component approach to fit a linear mixed model including a
75 set of covariance matrices representing: two genetic effects (G: common SNP-associated genetic effects
76 and K: pedigree-associated genetic effects not captured by the genotyped markers at a population level;
77 the inclusion of matrix K in the analyses allows to use the related individuals in the sample),
78 environmental effects reflecting impact of smoking (modelled as fixed or random effects), and genome-
79 by-smoking effects (GxSmk) representing sharing of both genetics (G) and environment (smoking, Smk),
80 and we estimated the proportion of variation that each component explained for seven obesity-related

measures: weight, body mass index (BMI), waist circumference (waist), hip circumference (hips), waist-to-hip ratio (WHR), fat percentage (fat%), and HDL cholesterol (HDL) as well as height, to serve as a negative control. We defined the environment using either self-reported questionnaire data or its associated methylation signature as a proxy. A summary of the experimental design used in this study is shown in Figure 1. For more detailed information, see Methods.



Models	Covariates (Fixed Effects)		
	centre + age + sex	*centre + age + sex + smoking*	*centre + age + sex-by-smoking*
Genetic	G + K		
Genetic + Environment	G + K + Smk	G + K	G + K
Genetic + Environment + Interaction	G + K + Smk + GxSmk	G + K + GxSmk	G + K + GxSmkxSex
Genetic + Methylation	G + K + M	G + K + M	G + K + M
Genetic + Methylation + Interaction	G + K + M + GxM	G + K + M + GxM	G + K + M + GxMxSex
Full	G + K + Smk + M + GxSmk + GxM	G + K + M + GxSmk + GxM	

Figure 1. Summary of the experimental design of the study. The panels (above) represent the genetic and environmental components contributing to trait variation and used in the models (table below). Each cell shows the included random effects in each combination of model (row) and fixed effects (columns). G: Genomic, K: Kinship, GxSmk: Genome-by-Smoking, M: Methylation, GxM: Genome-by-Methylation, GxSmkxSex: Genome-by-Smoking-by-Sex, GxMxSex: Genome-by-Methylation-by-Sex. Models applied to different data sets varied depending on data availability.

Self-reported smoking status.

Generation Scotland

Figure 2 shows the estimates of the proportion of BMI, fat percentage, and HDL variance explained by different sources included in the linear mixed models in ~18K individuals in Generation Scotland

98 (GS18K). Results for other traits are displayed in Table 1, Supplementary Figure 1, and full details of the
99 analyses for all traits including estimates, standard errors, and log-likelihood ratio tests (LRT) are shown
100 in Supplementary Table 1.



101
102 **Figure 2. Proportion of trait variation explained by genetic and interaction sources in GS18K**. Proportion of BMI,
103 fat percentage, and HDL variance (y-axis) explained by each of the genetic and interaction sources in the
104 corresponding models (x-axis). G: Genomic, K: Kinship, GxSmk: Genome-by-Smoking.

105 The heritability estimates of all analysed traits (i.e., proportion of the variance captured by G and K
106 matrices together) are consistent with previous estimates in the same cohort[37]. The estimated
107 contributions of smoking status (and the other covariates) to trait variation ranged between 0.35% (for
108 height, assessed as a negative control, as we do not expect to find the same type of effects as with
109 obesity-related measures) and 1.2% (for HDL cholesterol) and are shown in Supplementary Table 2.
110 When included as random effect, smoking explained between 0.1% (for height) and 2.5% (for HDL
111 cholesterol) of trait variation (Supplementary Table 1). Our models identified significant genome-by-

smoking interactions for weight, BMI, fat percentage and HDL cholesterol (with log-likelihood ratio tests showing that the models including the interaction were significantly better), explaining between 4 and 8% of trait variation (Table 1), similar to the values of Robinson et al.[12] for BMI. When the interactions included sex (genome-by-smoking-by-sex interactions) the component was significant for all traits, and explained variance ranging between 2-9% (Supplementary Table 2).

Trait	Source	GS18K			UKB Meta Analysis		
		Var	SE	LRT P	Var	SE	P
Height	G	0.483	0.022		0.629	0.009	
Height	K	0.429	0.024		0.328	0.006	
Height	GxSmk	0.012	0.014	0.2041	0.001	0.003	0.7640
Weight	G	0.270	0.024		0.355	0.007	
Weight	K	0.302	0.027		0.242	0.018	
Weight	GxSmk	0.049	0.021	0.0098	0.022	0.008	0.0050
BMI	G	0.258	0.024		0.318	0.008	
BMI	K	0.286	0.028		0.236	0.021	
BMI	GxSmk	0.039	0.021	0.0336	0.025	0.007	0.0009
Waist	G	0.181	0.024		0.261	0.004	
Waist	K	0.313	0.028		0.214	0.021	
Waist	GxSmk	0.023	0.022	0.1534	0.017	0.007	0.0119
Hips	G	0.212	0.024		0.296	0.009	
Hips	K	0.271	0.028		0.179	0.028	
Hips	GxSmk	0.027	0.023	0.1185	0.020	0.007	0.0048
WHR	G	0.130	0.023		0.217	0.005	
WHR	K	0.198	0.027		0.151	0.013	
WHR	GxSmk	0.019	0.023	0.2011	0.012	0.006	0.0437
Fat%	G	0.236	0.025		0.301	0.006	
Fat%	K	0.241	0.028		0.224	0.013	
Fat%	GxSmk	0.059	0.023	0.0036	0.021	0.005	0.0000
HDL	G	0.250	0.024			NA	
HDL	K	0.265	0.027			NA	
HDL	GxSmk	0.076	0.022	0.0002		NA	

Table 1. Summary of interaction results for all cohorts. Results of GKGxSmk model for all traits in GS18K and meta-analysis of the recruitment centre-based sub-cohorts in UK Biobank. The table shows, for each trait, the proportion of the phenotypic variance explained (Var), its standard error (SE), the log-likelihood ratio test P value (LRT P, only for the interaction), the meta-analysis P value (P), for each of the components in the model: Genetic (G), Kinship (K) and genome-by-smoking interaction (GxSmk). Highlighted P values indicate nominally significant results for the GxSmk component.

125

126 *UK Biobank*

127 We sought to replicate the results observed in Generation Scotland with data from the UK Biobank
128 cohort (UKB). Analyses were run in four sub-cohorts for computational reasons (G1, G2, G3 and G4,
129 grouping individuals in geographically close recruitment centres; for more information see Methods and
130 Supplementary Table 3), with the two sexes considered jointly and separately in three different analyses
131 (the sample size of these groups permitted estimates to be obtained with the two sexes separately).
132 Individual sub-cohort analyses were meta-analysed.

133 The estimated contributions of self-reported smoking status (and other covariates) to trait variation in
134 UK Biobank are shown in Supplementary Table 2. These were similar to the ones observed in Generation
135 Scotland, varying between 0.2% (for height) and 1.4% (for waist-to-hip ratio).

136 Figure 3 shows the proportion of BMI variance explained by the genome-by-smoking interactions in
137 each of the cohorts and sub-cohorts (Generation Scotland, four UK Biobank groups and the UK Biobank
138 meta-analysis). Results for other traits are displayed in Supplementary Figure 2 and full details of the
139 analyses for all traits including estimates, standard errors and log-likelihood ratio tests are shown in
140 Supplementary Tables 4, 5 and 6. Results for the genome-by-smoking-by-sex interactions are shown in
141 Supplementary Figure 3 and Supplementary Table 7.



Figure 3. Proportion of BMI variation explained by Genome-by-Smoking interactions across all cohorts and sub-cohorts. The plot shows the proportion of BMI variance (the bars represent standard errors) explained by the genome-by-smoking interaction (x-axis) in the mixed model analyses across cohorts (y-axis). Panels from top to bottom represent cohorts: Generation Scotland (GS), UK Biobank (UKB), UK Biobank females (UKB_F) and UK Biobank males (UKB_M). Blue coloured data points show sub-cohort results, green coloured data points show meta-analyses of the corresponding panel sub-cohorts.

Meta-analyses of the sub-cohorts showed significant genome-by-smoking interactions in all traits except for height when analysing both sexes together and males separately, whereas in females, only fat percentage showed a significant effect of the interaction. Similarly, the genome-by-smoking-by-sex interactions were significant for all traits but height. Genome-by-smoking-by-sex interaction effects explained between 2 and 6% of the observed variation.

Smoking-associated methylation

To explore the value of DNA methylation data as a proxy for environmental variation, we modelled similarity between individuals based on their DNA methylation levels at a subset of 62 CpG sites previously associated with smoking[19,34] and which had heritabilities lower than 40%, aiming to target

159 methylation variation that is predominantly capturing environmental variation (for details see
160 Methods). To show that our models can provide accurate estimates we performed a series of
161 simulations. Details and results for those are shown in Supplementary Text 1.

162 Figure 4 shows the estimates of the proportion of BMI variance explained by different sources included
163 in the mixed linear models in ~9K individuals in Generation Scotland (GS9K - right panel) including
164 models with methylation and genome-by-methylation interactions for models with self-reported
165 smoking status fitted as a fixed effect. Results for other traits are displayed in Supplementary Figure 1
166 and full details of the analyses for all traits including estimates, standard errors and log-likelihood ratio
167 tests, and results for smoking status fitted as a random effect are shown in Supplementary Table 8.
168 Inclusion of the methylation covariance matrix improved the models for all traits and explained 0.7% of
169 the variance for height and between 3-5% of the variance for obesity-related traits. After including
170 smoking-associated methylation variation, the variation explained by self-reported smoking status
171 dropped to zero for all traits (Supplementary Table 8, Model=GKEM). When exploring the interactions
172 with self-reported smoking status, the estimates in the subset of individuals with methylation data
173 available (N ~ 9K) are substantially larger than in the whole cohort. For example, for BMI, the size of the
174 genome-by-smoking component increased from 4% (GxSmk) to 13% (GxM), however, due to the large
175 standard errors, these two estimates are not significantly different from each other. Inclusion of the
176 genome-by-methylation interaction component nominally improved the model fit for weight, BMI, and
177 waist circumference, with estimates of the interaction component of over 20% of the estimates are
178 large. When fitting jointly the two interaction components (genome-by-smoking and genome-by-
179 methylation) the estimates were not significant for either interaction component (or just nominally
180 significant in the case of genome-by-methylation for BMI). The genome-by-methylation component was
181 also not significant for any trait.



Figure 4. Proportion of BMI variation explained by genetic, environmental and methylation sources in GS9K. Proportion of BMI variance (y-axis) explained by each of the genetic, environmental and interaction sources in the corresponding models (x-axis). G: Genomic, K: Kinship, GxSmk: Genome-by-Smoking, M: Smoking associated methylation, GxM: Genome-by-Methylation, GxSmkxSex: Genome-by-Smoking-by-Sex, GxMxSex: Genome-by-Methylation-by-Sex.

Discussion

Most complex diseases have moderate heritabilities, with various environmental sources of variation, for example, lifestyle and socioeconomic differences between individuals, also contributing to disease risk[5]. These diseases, particularly obesity, pose major challenges for public health and are associated with heavy economic burdens[3,4,38]. To prevent the problems resulting from complex diseases, effective personalised approaches that help individuals to reach and maintain a healthy lifestyle are required. To achieve that aim, knowledge of environmental effects and gene-by environment interactions (GxE, i.e., understanding the differential effects of an environmental exposure on a trait in individuals with different genotypes[39]) is required. This is a challenge, particularly for environmental factors that are not

199 easy to measure, or that are measured with a lot of error. It has previously been assumed that GxE
200 effects contribute to variation in obesity-related traits[6,8], but the total contribution to trait variation was
201 not known. Previous analyses exploring GxE in obesity, as well as other traits, took advantage of
202 particular individual genetic variants with known effects, or constructed polygenic scores, combining
203 several genetic variants which reflect genetic risks for the individuals[40,41]. Here we analysed
204 contributions of interactions between the genome (as a whole) with smoking, both using self-reported
205 measures of smoking and methylation data as a proxy for smoking.

206 Our estimates of the effects of genome-by-smoking interactions in obesity-related traits are larger than
207 those estimated in Shin and Lee [17] but in line with Robinson et al. [12] for BMI. However, our analyses
208 indicate that the magnitude is substantially different in the two sexes, with interactions playing a bigger
209 role in males for most traits studied (weight, waist, hips, fat%). Joint Analysis of males and females
210 provides less accurate estimates, suggesting that splitting the sexes or modelling the interactions with
211 sex is a more sensible way of analysing the data. The estimates of the variance explained by the
212 interaction components obtained from the genome-by-methylation analyses were large, with also large
213 standard errors. These results, despite not being significant after multiple correction testing, are
214 potentially interesting and should be investigated further. Some studies have suggested that there is
215 potential confounding between interaction and covariance effects in linear mixed models. The CpG sites
216 used to model the methylation similarity between individuals were previously corrected for genomic
217 effects (see methods) removing potential covariance between the genetic and methylation effects [42,43].

218 We estimated that the impact of genome-by-smoking interaction ranges from between 5 to 10% of
219 variation in the studied traits with the exception of height, which we used as a negative control. Our
220 results suggest a larger interaction component in traits associated with weight (BMI, weight, waist, hips)
221 than in those more related to adiposity (waist-to-hip ratio, fat percentage). Biological interpretation of
222 these interactions implies that some genes contributing to obesity differences between individuals have
223 different effects depending on smoking status. This could be mediated in several ways, for example, via

224 genetic variants that affect both obesity and smoking. Some metabolic factors associated with food
225 intake, such as leptin, are suspected to play a role in smoking behaviours, and rewarding effects of food
226 and nicotine are partly mediated by common neurobiological pathways[44]. For example, if these common
227 genetic architectures balance the two behaviours (i.e., more tobacco consumption leading to eating
228 less[44]) the genetic effects of obesity-related traits will be different depending on the smoking status.
229 The interactions could also be driven by gene-by-gene interactions (GxG), i.e., genetic variants affecting
230 obesity modulated by smoking associated genetic variants. Under this scenario smoking status would
231 be capturing smoking associated variants, and the genome-by-smoking interaction would represent
232 GxG instead of GxE. However, given the relatively small heritability of tobacco smoking (SNP heritability
233 ~18%[45]), it is unlikely that all the variation we detected is driven by GxG.

234 One of the sub-groups of UK Biobank (G3) showed consistently non-significant estimates of the
235 interactions for all traits. The different behaviour for this cohort is not driven by characteristics like the
236 proportion of smokers (Supplementary table 3), or by its genetic stratification. Without any other
237 evidence we cannot attribute these systematic lower estimates to anything but chance.

238 When we estimated the effect of smoking using the methylomic proxy (62 CpG sites associated with
239 smoking from two independent studies[19,34]), the smoking associated variance increased substantially for
240 all traits (from 2% to 6% for BMI). The methylation component captured the same variance as the self-
241 reported component and some extra variation (Supplementary table 8b). This increase in variation
242 captured could be due to a better ability to separate differences between different levels of smoking
243 (e.g., the self-reported status does not include amount of tobacco smoked, while the methylation might
244 be able to capture this information better). These smoking associated CpG sites could also be picking
245 up variation from other environmental sources that are not exclusively driven by smoking, but
246 correlated with it, such as alcohol intake. When checking in the literature for other possible associations
247 between the 62 CpG sites and other environmental measures (Supplementary Table 9), 20 of these
248 CpGs have previously been associated with age, 15 with alcohol intake or alcohol dependence, 11 with

249 educational attainment, 10 with different types of cancer; and a few with other diseases[46,47]. Unlike for
250 smoking, for most of these associations with other traits, it is unclear if they are casual, or if they could
251 as well be driven by smoking (e.g., alcohol consumption is associated with smoking and picking up a
252 smoking signal).

253 The fact that variation in obesity can be explained by CpG sites associated with smoking does not imply
254 a causal effect of smoking or methylation on obesity. Methylation is affected by both genetic and
255 environmental effects. Here we selected a subset of CpG sites with moderate to small heritability (lower
256 than 40%, Supplementary Table 9) and we modelled them jointly with a genomic similarity matrix,
257 making it unlikely that the variance picked up by the methylation matrix is genetic in nature. While most
258 changes in methylation at these CpG sites are thought to be causally driven by smoking[19], associations
259 between methylation and other complex traits, such as BMI, are less well characterised and mostly likely
260 to be reversely caused[48] (i.e., BMI affecting methylation), however, since our aim was to use methylation
261 as a proxy for the environment, causality does not impact the conclusion of the study. It is, however,
262 important to notice the variable nature of the methylation data, which will change during the life course
263 of individuals unlike the genetics of the individuals, making the inclusion of methylation, measured far
264 back in time, less relevant in a prediction framework[49]. Although this approach should be useful in other
265 populations, a relevant set of CpG sites should be selected reflecting demographic and ethnic relevant
266 associations[50].

267 To conclude, we showed that methylation data can be used as a proxy to assess smoking contributions
268 to complex trait variation. We used DNA methylation levels at CpG sites associated with smoking as a
269 proxy for smoking status to assess the contribution of smoking to variation in obesity-related traits. This
270 principle could be extended to take advantage of the wealth of uncovered associations between various
271 *omics* and environmental exposures of interest, particularly for those that are difficult to measure. In
272 humans, relevant interactions could be investigated by exploiting the links between methylation and
273 alcohol intake, metabolomics and diets, the gut microbiome, and diets, etc., and expanding to other

species, between the gut microbiome and greenhouse emissions in cattle. This could help expanding our knowledge on their contribution to complex phenotypes, and potentially, help understand the underlying biology and to improve prediction and prognosis.

277 ## Methods

278 ### Data.

279 *Generation Scotland.* We used data from Generation Scotland: Scottish Family Health Study (GS)[51,52].
280 Ethical approval for the study was given by the NHS Tayside committee on research ethics (ref:
281 05/s1401/89). Governance of the study, including public engagement, protocol development and
282 access arrangements, was overseen by an independent advisory board, established by the Scottish
283 government. Research participants gave consent to allow both academic and commercial research.
284 Individuals were genotyped with the Illumina HumanOmniExpressExome-8 v1.0 or v1.2. We used PLINK
285 version 1.9b2c[53] to exclude SNPs that had a missingness > 2% and a Hardy-Weinberg Equilibrium test
286 $P < 10^{-6}$. Markers with a minor allele frequency (MAF) smaller than 0.05 were discarded. Duplicate
287 samples, individuals with gender discrepancies and those with more than 2% missing genotypes were
288 also removed. The resulting data set was merged with the 1092 individuals of the 1000 Genomes
289 population[54] and a principal component analysis was performed using GCTA[55]. Individuals more than 6
290 standard deviations away from the mean of principal component 1 and principal component 2 were
291 removed as potentially having African/Asian ancestry as shown in Amador et al.[56]. After quality control,
292 individuals had genotypes for 519,819 common SNP spread over the 22 autosomes. Of the ~24,000
293 individuals in GS, the number of individuals with complete information for smoking and other covariates
294 was 18,522 so we used this core set of samples for the analyses in order to allow comparisons between
295 the models, we refer to this set of samples as GS18K.

296 *UK Biobank*. Data access to UK Biobank was granted under MAF 19655. The UK Biobank database include
297 502,664 participants, aged 40–69, recruited from the general UK population across 22 centres between
298 2006 and 2010[57]. They underwent extensive phenotyping by questionnaire and clinic measures and
299 provided a blood sample. All participants gave written informed consent, and the study was approved
300 by the North West Multicentre Research Ethics Committee. Phenotypes and genotypes were
301 downloaded direct from UK Biobank. UK Biobank participants were genotyped on two slightly different

302 arrays and quality control was performed by UK Biobank. The two are Affymetrix arrays with 96% of
303 SNPs overlap between both. Further information about the quality control can be found in the UK
304 Biobank website (https://www.ukbiobank.ac.uk/register-apply/). Only genetically white British
305 individuals were used in the analyses. The total number of individuals with complete information for
306 measures of interest was 374,453. Genotypes were available for 534,427 common markers spread over
307 the 22 autosomes.

308 For computational reasons, UKB individuals were split in four sub-cohorts to be analysed separately.
309 The grouping was based in latitudinal differences between the assessment centres the individuals
310 attended. Number of individuals and assessment centres are shown in Supplementary Table 3.

311 **Phenotypes.**

312 *Generation Scotland*. We used measured phenotypes for eight traits: height, weight, body mass index
313 (BMI, computed as weight/height^2), waist circumference (waist), hip circumference (hips), waist-to-hip
314 ratio (WHR, computed as waist/hips), bio-impedance analysis fat (fat%), and HDL cholesterol.
315 Phenotypes with values greater or smaller than the mean ± 4 standard deviations (after transformation
316 and adjusting for sex, age and age^2) were set to missing. The traits were pre-adjusted for the effects of
317 sex, age, age^2, clinic where the measures were taken, and a rank-based inverse normal transformation
318 was performed on the residuals. These values were used in all the analyses.

319 *UK Biobank*. We used measured phenotypes for anthropometric traits: height, weight, body mass index
320 (BMI, computed as weight/height^2),waist circumference (waist), hip circumference (hips), waist-to-hip
321 ratio (WHR, computed as waist/hips), body fat percentage (fat%)Phenotypes with values greater or
322 smaller than the mean ± 4 standard deviations (after transformation and adjusting for sex, age and age^2)
323 were set to missing. The traits were pre-adjusted for the effects of sex, age, age^2, clinic where the
324 measures were taken, and a rank-based inverse normal transformation was performed on the residuals.
325 These values were used in all the analyses.

326 **Smoking status.**

327 We used self-reported smoking status on both cohorts. Individuals were classified with respect of
328 smoking as "never smoked", "ex-smoker" and "current smoker" for Generation Scotland, and as "never
329 smoked", "ex-smoker", "current smoker", and "occasional smoker" for UK Biobank. The number of
330 individuals in each category are shown in Supplementary Table 3.

331 **DNA Methylation data.**

332 DNA methylation data is available for a subset of 9,537 participants from the GS cohort, as part of the
333 Stratifying Resilience and Depression Longitudinally (STRADL) project[58]. From those, we used N = 8,821
334 individuals that had complete information for all the same set of covariates as used in the smoking status
335 analysis. We refer to this subset of individuals as GS9K. DNA methylation was measured at 866,836 CpGs
336 from whole blood genomic DNA, using the Illumina Infinium MethylationEPIC array. Quality control was
337 performed using R (version 3.6.0)[59] , and packages *shinyMethyl*[60] and *meffil*[61]. We removed outliers
338 based on overall array signal intensity and control probe performance and samples showing a mismatch
339 between recorded and predicted sex. We removed samples with more than 0.5% of sites with a
340 detection p-value of > 0.01; and probes with more than 5% samples with a bead count smaller than 3.
341 Normalization was performed using the R package *minfi*[62], that produced methylation M-values that
342 were used in downstream analyses. For each methylation site, two linear mixed model were used to
343 remove effects of technical and biological factors correcting for technical variation, i.e., Sentrix id,
344 Sentrix position, batch, clinic, appointment date, year and weekday of the blood extraction, and 20
345 principal components of the control probes; and biological variation, i.e., sex, age, estimated cell
346 proportions (CD8T, CD4T, NK, B Cell, Mono, and Gran cells proportions based on Houseman, et al. [63]),
347 and two genetic (Genetic and Kinship) and three common environment (Family, Couples, Siblings)
348 effects. For more information see Xia et al[37] and Zeng et al[18]. The residual values of those corrections
349 were used for subsequent analyses.

350 *Smoking associated CpG sites.* We selected a subset of CpG sites identified in two epigenome-wide
351 association studies of tobacco consumption[19,34]. We selected CpG sites with a p-value lower than 10^{-7} in
352 both Ambatipudi et al.[19] (associations between CpG sites and differences between groups: smokers *v*
353 non-smokers, smokers *v* ex-smokers, ex-smokers *v* non-smokers) and in Joehanes et al.[34] (associations
354 between CpG sites and dosage of tobacco smoked) to obtain a subset of CpG sites confidently associated
355 with smoking (i.e., from two sources). We identified those CpG sites with heritabilities lower than 40%
356 in Generation Scotland (as measured in the last step of the quality control of the data, see below) that
357 are available in Generation Scotland. The list of 62 CpG sites is available in Supplementary Table 9.

358 Covariance Matrices.

359 To model the different sources of variance we used a set of covariance matrices representing similarity
360 between individuals based on genetic components, environmental components, or both.

361 *Genetic matrices*: **G** is a genomic relationship matrix (GRM) reflecting the genetic similarity between
362 individuals[16,64]. **K** is a matrix representing pedigree relationships as in Zaitlen et al.[65]. It is a modification
363 of **G** obtained by setting those entries in G lower than 0.025 to 0.

364 *Smoking matrices*: **SMK** is a matrix representing common environmental effects shared between
365 individuals with same smoking status i.e., **SMK** contains a value of 1 between individuals in the same
366 smoking category and a 0 between individuals in different categories.

367 *Gene-Environment interaction matrices*: **GxSmk** is a matrix representing genome-by-smoking
368 interactions. It was computed as the cell-by-cell product (Hadamard or Schur product) of the
369 corresponding **G** and **SMK** matrices. For an element of the **GxSmk** matrix, if the corresponding **G** or the
370 **SMK** elements are close to zero, the **GxSmk** term will be zero or close to zero as well. Therefore,
371 similarity between individuals due to the interactions represented in the **GxSmk** matrices requires
372 similarity at both genetic and environmental level. This method resembles a reaction norm modelling
373 approach[66].

374 *Methylation-derived matrices*: **M** is a matrix representing similarity between individuals based on DNA
375 methylation levels at 62 smoking associated CpG sites (see *Smoking associated CpG sites* above). A
376 similarity matrix was created using OSCA v 0.45[67] using algorithm 3 (i.e., iteratively standardizing probes
377 and individuals). **GxM** is a genome-by-smoking interaction matrix computed as a Hadamard product of
378 **G** and **M**.

379 **Analyses**

380 We performed several variance component analyses using GCTA[55], based in the following linear mixed
381 models:

382 **(1)** $y = X\beta + g_g + g_{kin} + \varepsilon$

383 **(2)** $y = X\beta + g_g + g_{kin} + w_L + \varepsilon$

384 **(3)** $y = X\beta + g_g + g_{kin} + w_L + gw + \varepsilon$

385 **(4)** $y = X\beta + g_g + g_{kin} + gw + \varepsilon$

386 where y is an $n \times 1$ vector of observed phenotypes with n being the number of individuals, β is a vector
387 of fixed effects and **X** is its design matrix, g_g is an $n \times 1$ vector of the total additive genetic effects of the
388 individuals captured by genotyped SNPs with $g_g \sim N(0, \mathbf{G}\sigma^2_g)$; g_{kin} is an $n \times 1$ vector of the extra genetic
389 effects associated with the pedigree for relatives with $g_{kin} \sim N(0, \mathbf{K}\sigma^2_k)$. w is a $n \times 1$ vector representing
390 the common environmental effects of smoking, with $w \sim N(0, \mathbf{SMK}\sigma^2_w)$. gw is a $n \times 1$ vector representing
391 interactions between markers and environments with $gw \sim N(0, \mathbf{GxSmk}\sigma^2_{gw})$. ε is an $n \times 1$ vector for the
392 residuals. The four basic models shown above were expanded to include all combinations of random
393 and fixed effects showed in Figure 1.

394 The estimates for variance explained by the genome-by-smoking components in the four sub-cohorts
395 of UK Biobank were meta-analysed using the R[59] package *metafor*[68].

396

Data availability

Generation Scotland data are available from the MRC IGC Institutional Data Access / Ethics Committee for researchers who meet the criteria for access to confidential data. Generation Scotland data are available to researchers on application to the Generation Scotland Access Committee (access@generationscotland.org). The managed access process ensures that approval is granted only to research which comes under the terms of participant consent which does not allow making participant information publicly available. UK Biobank data are available from: https://www.ukbiobank.ac.uk/register-apply/

References

1. Locke, A.E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197-206 (2015).
2. Qi, L. & Cho, Y.A. Gene-environment interaction and obesity. *Nutr. Rev.* **66**, 684-694 (2008).
3. Swinburn, B.A. *et al.* The global obesity pandemic: shaped by global drivers and local environments. *Lancet* **378**, 804-814 (2011).
4. Wang, Y.C., McPherson, K., Marsh, T., Gortmaker, S.L. & Brown, M. Health and economic burden of the projected obesity trends in the USA and the UK. *Lancet* **378**, 815-825 (2011).
5. Amador, C. *et al.* Regional variation in health is predominantly driven by lifestyle rather than genetics. *Nat. Commun.* **8**, 801 (2017).
6. Huang, T. & Hu, F.B. Gene-environment interactions and obesity: recent developments and future directions. *BMC Med. Genomics.* **8**, S2 (2015).
7. Tyrrell, J. *et al.* Gene–obesogenic environment interactions in the UK Biobank study. *Int. J. Epidemiol.* **46**, 559-575 (2017).
8. Cornelis, M.C. & Hu, F.B. Gene-Environment Interactions in the Development of Type 2 Diabetes: Recent Progress and Continuing Challenges. *Annu. Rev. Nutr.* **32**, 245-259 (2012).
9. Li, J., Li, X., Zhang, S. & Snyder, M. Gene-Environment Interaction in the Era of Precision Medicine. *Cell* **177**, 38-44 (2019).
10. Poveda, A. *et al.* The heritable basis of gene–environment interactions in cardiometabolic traits. *Diabetologia* **60**, 442-452 (2017).
11. Trzaskowski, M., Lichtenstein, P., Magnusson, P.K., Pedersen, N.L. & Plomin, R. Application of linear mixed models to study genetic stability of height and body mass index across countries and time. *Int. J. Epidemiol.* **45**, 417-423 (2016).
12. Robinson, M.R. *et al.* Genotype-covariate interaction effects and the heritability of adult body mass index. *Nat. Genet.* **49**, 1174-1181 (2017).
13. Bentley, A.R. *et al.* Multi-ancestry genome-wide gene–smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. *Nat. Genet.* **51**, 636-648 (2019).
14. Justice, A.E. *et al.* Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits. *Nat. Commun.* **8**, 14977 (2017).
15. Sung, Y.J. *et al.* A multi-ancestry genome-wide study incorporating gene–smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure. *Hum. Mol. Genet.* **28**, 2615-2633 (2019).

438 16. Yang, J. *et al.* Common SNPs explain a large proportion of the heritability for human height. *Nat.*
439 *Genet.* **42**, 565-569 (2010).
440 17. Shin, J. & Lee, S.H. GxEsum: genotype-by-environment interaction model based on summary
441 statistics. *bioRxiv* (2020).
442 18. Zeng, Y. *et al.* Parent of origin genetic effects on methylation in humans are common and influence
443 complex trait variation. *Nat. Commun.* **10**, 1383 (2019).
444 19. Ambatipudi, S. *et al.* Tobacco smoking-associated genome-wide DNA methylation changes in the
445 EPIC study. *Epigenomics* **8**, 599-618 (2016).
446 20. Sugden, K. *et al.* Establishing a generalized polyepigenetic biomarker for tobacco smoking. *Transl.*
447 *Psychiatry* **9**, 92 (2019).
448 21. Zhang, Y. & Kutateladze, T.G. Diet and the epigenome. *Nat. Commun.* **9**, 3375 (2018).
449 22. McRae, A.F. *et al.* Contribution of genetic variation to transgenerational inheritance of DNA
450 methylation. *Genome Biol.* **15**, R73 (2014).
451 23. van Dongen, J. *et al.* Genetic and environmental influences interact with age and sex in shaping
452 the human methylome. *Nat. Commun.* **7**, 11115 (2016).
453 24. Jones, P.A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat. Rev.*
454 *Genet.* **13**, 484-492 (2012).
455 25. Moore, L.D., Le, T. & Fan, G. DNA Methylation and Its Basic Function. *Neuropsychopharmacology*
456 **38**, 23-38 (2013).
457 26. Putiri, E.L. & Robertson, K.D. Epigenetic mechanisms and genome stability. *Clin. Epigenetics* **2**, 299-
458 314 (2011).
459 27. Greenberg, M.V.C. & Bourc'his, D. The diverse roles of DNA methylation in mammalian
460 development and disease. *Nat. Rev. Mol. Cell Biol.* **20**, 590-607 (2019).
461 28. Demerath, E.W. *et al.* Epigenome-wide association study (EWAS) of BMI, BMI change and waist
462 circumference in African American adults identifies multiple replicated loci. *Hum. Mol. Genet.* **24**,
463 4464-4479 (2015).
464 29. Wahl, S. *et al.* Epigenome-wide association study of body mass index, and the adverse outcomes
465 of adiposity. *Nature* **541**, 81 (2016).
466 30. Rask-Andersen, M. *et al.* Epigenome-wide association study reveals differential DNA methylation
467 in individuals with a history of myocardial infarction. *Hum. Mol. Genet.* **25**, 4739-4748 (2016).
468 31. Jin, Z. & Liu, Y. DNA methylation in human diseases. *Genes Dis.* **5**, 1-8 (2018).
469 32. Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol.* **14**, 3156 (2013).
470 33. Horvath, S. & Raj, K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing.
471 *Nat. Rev. Genet.* **19**, 371-384 (2018).

472 34. Joehanes, R. *et al.* Epigenetic Signatures of Cigarette Smoking. *Circ. Cardiovasc. Genet.* **9**, 436-447
473 (2016).
474 35. Lee, M.K., Hong, Y., Kim, S.-Y., London, S.J. & Kim, W.J. DNA methylation and smoking in Korean
475 adults: epigenome-wide association study. *Clin. Epigenetics* **8**, 103 (2016).
476 36. Gao, X., Jia, M., Zhang, Y., Breitling, L.P. & Brenner, H. DNA methylation changes of whole blood
477 cells in response to active smoking exposure in adults: a systematic review of DNA methylation
478 studies. *Clin. Epigenetics* **7**, 113 (2015).
479 37. Xia, C. *et al.* Pedigree- and SNP-Associated Genetics and Recent Environment are the Major
480 Contributors to Anthropometric and Cardiometabolic Trait Variation. *PLOS Genet.* **12**, e1005804
481 (2016).
482 38. Gortmaker, S.L. *et al.* Changing the future of obesity: science, policy, and action. *Lancet* **378**, 838-
483 847 (2011).
484 39. Ottman, R. Gene–Environment Interaction: Definitions and Study Design. *Prev. Med.* **25**, 764-770
485 (1996).
486 40. Young, A.I., Wauthier, F. & Donnelly, P. Multiple novel gene-by-environment interactions modify
487 the effect of FTO variants on body mass index. *Nat. Commun.* **7**, 12724 (2016).
488 41. Qi, Q. *et al.* Sugar-Sweetened Beverages and Genetic Risk of Obesity. *N. Engl. J. Med.* **367**, 1387-
489 1396 (2012).
490 42. Ni, G. *et al.* Genotype–covariate correlation and interaction disentangled by a whole-genome
491 multivariate reaction norm model. *Nat. Commun.* **10**, 2239 (2019).
492 43. Zhou, X., Im, H.K. & Lee, S.H. CORE GREML for estimating covariance between random effects in
493 linear mixed models for complex trait analyses. *Nat. Commun.* **11**, 4208 (2020).
494 44. Chao, A.M., Wadden, T.A., Ashare, R.L., Loughead, J. & Schmidt, H.D. Tobacco Smoking, Eating
495 Behaviors, and Body Weight: a Review. *Curr. Addict. Rep.* **6**, 191-199 (2019).
496 45. Evans, L.M. *et al.* Genetic architecture of four smoking behaviors using partitioned h^2_{SNP}. *medRxiv*,
497 2020.06.17.20134080 (2020).
498 46. Battram, T. *et al.* The EWAS Catalog: a database of epigenome-wide association studies. .
499 https://doi.org/10.31219/osf.io/837wn (2021).
500 47. Li, M. *et al.* EWAS Atlas: a curated knowledgebase of epigenome-wide association studies. *Nucleic*
501 *Acids Res* **47**, D983-d988 (2019).
502 48. Reed, Z.E., Suderman, M.J., Relton, C.L., Davis, O.S.P. & Hemani, G. The association of DNA
503 methylation with body mass index: distinguishing between predictors and biomarkers. *Clin.*
504 *Epigenetics* **12**, 50 (2020).

505 49. Trejo Banos, D. *et al.* Bayesian reassessment of the epigenetic architecture of complex traits. *Nat.*
506 *Commun.* **11**, 2865 (2020).
507 50. Popejoy, A.B. *et al.* The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in
508 genomics. *Hum. Mutat.* **39**, 1713-1720 (2018).
509 51. Smith, B.H. *et al.* Cohort profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The
510 study, its participants and their potential for genetic research on health and illness. *Int. J.*
511 *Epidemiol.* **42**, 689-700 (2012).
512 52. Smith, B.H. *et al.* Generation Scotland: the Scottish Family Health Study; a new resource for
513 researching genes and heritability. *BMC Med. Genet.* **7**, 74 (2006).
514 53. Chang, C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets.
515 *GigaScience* **4**, 7 (2015).
516 54. The 1000 Genomes Project Consortium. A map of human genome variation from population-scale
517 sequencing. *Nature* **467**, 1061-1073 (2010).
518 55. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex trait
519 analysis. *Am. J. Hum. Genet.* **88**, 76-82 (2011).
520 56. Amador, C. *et al.* Recent genomic heritage in Scotland. *BMC Genomics* **16**(2015).
521 57. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range
522 of Complex Diseases of Middle and Old Age. *PLOS Med.* **12**, e1001779 (2015).
523 58. Navrady, L.B. *et al.* Cohort Profile: Stratifying Resilience and Depression Longitudinally (STRADL):
524 a questionnaire follow-up of Generation Scotland: Scottish Family Health Study (GS:SFHS). *Int. J.*
525 *Epidemiol.* **47**, 13-14g (2017).
526 59. R Core Team. *R: A language and environment for statistical computing*, (R Foundation for Statistical
527 Computing, Vienna (Austria), 2020).
528 60. Fortin, J., Fertig, E. & Hansen, K. shinyMethyl: interactive quality control of Illumina 450k DNA
529 methylation arrays in R [version 2; peer review: 2 approved]. *F1000Research* **3**(2014).
530 61. Min, J.L., Hemani, G., Davey Smith, G., Relton, C. & Suderman, M. Meffil: efficient normalization
531 and analysis of very large DNA methylation datasets. *Bioinformatics* **34**, 3983-3989 (2018).
532 62. Aryee, M.J. *et al.* Minfi: a flexible and comprehensive Bioconductor package for the analysis of
533 Infinium DNA methylation microarrays. *Bioinformatics* **30**, 1363-1369 (2014).
534 63. Houseman, E.A. *et al.* DNA methylation arrays as surrogate measures of cell mixture distribution.
535 *BMC Bioinf.* **13**, 86 (2012).
536 64. VanRaden, P.M. Efficient methods to compute genomic predictions. *J. Dairy Sci.* **91**, 4414-4423
537 (2008).

538 65. Zaitlen, N. *et al.* Using extended genealogy to estimate components of heritability for 23
539 quantitative and dichotomous traits. *PLOS Genet.* **9**, e1003520 (2013).
540 66. Jarquín, D. *et al.* A reaction norm model for genomic selection using high-dimensional genomic
541 and environmental data. *Theor. Appl. Genet.* **127**, 595-607 (2014).
542 67. Zhang, F. *et al.* OSCA: a tool for omic-data-based complex trait analysis. *Genome Biol.* **20**, 107
543 (2019).
544 68. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *J Stat Softw* **36**, 48
545 (2010).

Acknowledgements

The authors want to acknowledge the Medical Research Council (MRC) UK for funding (core funding: MC_UU_00007/10, MC_PC_U127592696 and MC_PC_U127561128), and a *Wellcome Trust Investigator Award* to AMM (220857/Z/20/Z). Generation Scotland has received core funding from the Chief Scientist Office of the Scottish Government Health Directorates CZD/16/6 and the Scottish Funding Council HR03006. Genotyping of the GS samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was funded by the UK MRC and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" (STRADL) Reference 104036/Z/14/Z). We are grateful to all the families who took part, the general practitioners, and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. The research was conducted using the UK Biobank Resource under Application number 19655.

Author Contributions

CA, CHS, and PN conceived and designed the experiments presented in this manuscript. DP and AMM contributed to conceive and design the study population and phenotypic recording. DP, AMM, and JFW contributed to oversight of the study and sample collection. CA conducted the analyses. YZ, MB, RW, KE, AC, CH, managed and maintained the data and performed quality control and data annotation. CA, PN, CSH wrote the paper. All authors discussed results, read, and approved the final manuscript.

Competing interests

AMM. has received research support from Eli Lilly and Company, Janssen and the Sackler Trust and speaker fees from Illumina and Janssen.

Figure and Table captions.

Figure 1. Summary of the experimental design of the study. The panels (above) represent the genetic and environmental components used in the models (table below). Each cell shows the included random effects in each combination of model (row) and fixed effects (columns). G: Genomic, K: Kinship, GxSmk: Genome-by-Smoking, M: Methylation, GxM: Genome-by-Methylation, GxSmkxSex: Genome-by-Smoking-by-Sex, GxMxSex: Genome-by-Methylation-by-Sex.

Proportion of trait variation explained by genetic and environmental the different sources in Generation Scotland (GS18K). Proportion of BMI, fat percentage, and HDL variance (y-axis) explained by each of the genetic, environmental and interaction sources in the corresponding models (x-axis). GS data (Nind≈ 18K) with complete environmental information. G: Genomic, K: Kinship, GxSmk: Genome-by-Smoking, M: Smoking associated methylation, GxM: Genome-by-Methylation, GxSmkxSex: Genome-by-Smoking-by-Sex, GxMxSex: Genome-by-Methylation-by-Sex.

Figure 3. Proportion of BMI variation explained by Genome-by-Smoking interactions across all cohorts and sub-cohorts. The plot shows the proportion of BMI variance (the bars represent standard errors) explained by the genome-by-smoking interaction (x-axis) in the mixed model analyses across cohorts (y-axis). Panels from top to bottom represent cohorts: Generation Scotland (GS), UK Biobank (UKB), UK Biobank females (UKB_F) and UK Biobank males (UKB_M). Blue coloured data points show sub-cohort results (GS18K and UKB subgroups G1-G4), green coloured data points show meta-analyses of the corresponding panel sub-cohorts.

Figure 4. Proportion of BMI variation explained by genetic, environmental and methylation sources in GS9K. Proportion of BMI variance (y-axis) explained by each of the genetic, environmental and interaction sources in the corresponding models (x-axis). G: Genomic, K: Kinship, GxSmk: Genome-by-Smoking, M: Smoking associated methylation, GxM: Genome-by-Methylation, GxSmkxSex: Genome-by-Smoking-by-Sex, GxMxSex: Genome-by-Methylation-by-Sex.

Table 1. Summary of interaction results for all cohorts. Results of GKGxSmk model for a selected group of tested traits in GS18K, GS9K and metanalysis of the four cohorts in UK Biobank. The table shows, for each trait, proportion of the phenotypic variance explained (Var), standard error (SE), Significance of the t-statistic (Sig, P), P value for the log-likelihood ratio test (LRT P, only for the interaction) by each of the components in the model: Genetic (G), Kinship (K) and genome-by-smoking interaction (GxSmk). Highlighted P values indicate nominally significant results for the GxSmk component.

Supplementary Figure and Table captions.

Supplementary Figure 1. Proportion of trait variation explained by the different sources in Generation Scotland (GS) in each of the eight traits studied. Proportion of trait variance (y-axis) explained by each of the genetic, environmental and interaction sources in the corresponding models (x-axis). Left panel: GS data (Nind≈18K) with complete environmental information. Right panel: GS data with methylation information (Nind≈9K). G: Genomic, K: Kinship, GxSmk: Genome-by-Smoking, M: Smoking associated methylation, GxM: Genome-by-Methylation, GxSmkxSex: Genome-by-Smoking-by-Sex, GxMxSex: Genome-by-Methylation-by-Sex.

Supplementary Figure 2. Proportion of trait variation explained by Genome-by-Smoking interactions across all cohorts and sub-cohorts in each of the eight traits studied. The plot shows the proportion of trait variance (the bars represent standard errors) explained by the genome-by-smoking interaction (x-axis) in the mixed model analyses across cohorts (y-axis). Panels from top to bottom represent cohorts: Generation Scotland (GS), UK Biobank (UKB), UK Biobank females (UKB_F) and UK Biobank males (UKB_M). Blue coloured data points show sub-cohort results (GS18K and UKB subgroups G1-G4), green coloured data points show meta-analyses of the corresponding panel sub-cohorts.

Supplementary Figure 3. Proportion of trait variation explained by Genome-by-Smoking-by-Sex interactions across all cohorts and sub-cohorts in each of the eight traits studied. The plot shows the proportion of BMI variance (the bars represent standard errors) explained by the genome-by-smoking-by-sex interaction (x-axis) in the mixed model analyses across cohorts (y-axis). Panels from top to bottom represent cohorts: Generation Scotland (GS), UK Biobank (UKB), UK Biobank females (UKB_F) and UK Biobank males (UKB_M). Blue coloured data points show sub-cohort results (GS18K and UKB subgroups G1-G4), green coloured data points show meta-analyses of the corresponding panel sub-cohorts.

Supplementary Table 1. Results for all models for GS18K cohort. A. Models with smoking fitted as a random effect. B. Models with smoking fitted as a random effect. The tables show, for each trait, proportion of the phenotypic variance explained (Var), standard error (SE), Significance of the t-statistic (Sig, P), P value for the log-likelihood ratio test (LRT P, only for the interactions) by each of the components in the model: Genetic (G), Kinship (K), Smoking (when fitted as a random effect, Smk), genome-by-smoking interaction (GxSmk), genome-by-smoking-by-sex interaction (GxSmkxSex), kinship-by-smoking interaction (KxSmk). Highlighted P values indicate nominally significant results for the interaction components.

629 **Supplementary Table 2. Variance explained by fixed effects.** Percentage of the phenotypic variance
630 explained by the fixed effects included in the models for each trait and cohort.

631 **Supplementary Table 3. Cohorts summaries**. Summary statistics (number of individuals in each category
632 or mean values) for the covariates included in the models for each of the analysed cohorts.

633 **Supplementary Table 4. Results for all models for the four UKB cohorts (joint sexes).** The tables show,
634 for each trait, proportion of the phenotypic variance explained (Var), standard error (SE), Significance
635 of the t-statistic (Sig, P), P value for the log-likelihood ratio test (LRT P, only for the interactions) by each
636 of the components in the model: Genetic (G), Kinship (K), genome-by-smoking interaction (GxSmk).
637 Highlighted P values indicate nominally significant results for the interaction components in each of the
638 four sub-cohorts of UK Biobank (G1, G2, G3, G4) and their Meta-Analyses.

639 **Supplementary Table 5. Results for all models for the four UKB cohorts (males).** The tables show, for
640 each trait, proportion of the phenotypic variance explained (Var), standard error (SE), Significance of
641 the t-statistic (Sig, P), P value for the log-likelihood ratio test (LRT P, only for the interactions) by each of
642 the components in the model: Genetic (G), Kinship (K), genome-by-smoking interaction (GxSmk).
643 Highlighted P values indicate nominally significant results for the interaction components in males from
644 each of the four sub-cohorts of UK Biobank (G1_M, G2_M, G3_M, G4_M) and their Meta-Analyses.

645 **Supplementary Table 6. Results for all models for the four UKB cohorts (females).** The tables show, for
646 each trait, proportion of the phenotypic variance explained (Var), standard error (SE), Significance of
647 the t-statistic (Sig, P), P value for the log-likelihood ratio test (LRT P, only for the interactions) by each of
648 the components in the model: Genetic (G), Kinship (K), genome-by-smoking interaction (GxSmk).
649 Highlighted P values indicate nominally significant results for the interaction components in females
650 from each of the four sub-cohorts of UK Biobank (G1_F, G2_F, G3_F, G4_F) and their Meta-Analyses.

651 **Supplementary Table 7. Results for all models for the four UKB cohorts (joint GxSmkxSex interactions).**
652 The tables show, for each trait, proportion of the phenotypic variance explained (Var), standard error
653 (SE), Significance of the t-statistic (Sig, P), P value for the log-likelihood ratio test (LRT P, only for the
654 interactions) by each of the components in the model: Genetic (G), Kinship (K), genome-by-smoking-by-
655 sex interaction (GxSmkxSex). Highlighted P values indicate nominally significant results for the
656 interaction components in each of the four sub-cohorts of UK Biobank (G1, G2, G3, G4) and their Meta-
657 Analyses.

658 **Supplementary Table 8. Results for all models for GS9K cohort.** A. Models with smoking fitted as a
659 random effect. B. Models with smoking fitted as a random effect. The tables show, for each trait,
660 proportion of the phenotypic variance explained (Var), standard error (SE), Significance of the t-statistic

661 (Sig, P), P value for the log-likelihood ratio test (LRT P, only for the interactions) by each of the
662 components in the model: Genetic (G), Kinship (K), Smoking (when fitted as a random effect, Smk),
663 genome-by-smoking interaction (GxSmk), genome-by-smoking-by-sex interaction (GxSmkxSex), kinship-
664 by-smoking interaction (KxSmk). Highlighted P values indicate nominally significant results for the
665 interaction components.

666 **Supplementary Table 9. Smoking associated CpG sites information.** Name, chromosome, location,
667 heritability, and trait associations of the 62 CpG sites associated with smoking. Trait associations were
668 extracted from the EWAS Atlas database.



Models	Covariates (Fixed Effects)		
	centre + age + sex	*centre + age + sex + smoking*	*centre + age + sex-by-smoking*
Genetic	G + K		
Genetic + Environment	G + K + Smk	G + K	G + K
Genetic + Environment + Interaction	G + K + Smk + GxSmk	G + K + GxSmk	G + K + GxSmkxSex
Genetic + Methylation	G + K + M	G + K + M	G + K + M
Genetic + Methylation + Interaction	G + K + M + GxM	G + K + M + GxM	G + K + M + GxMxSex
Full	G + K + Smk + M + GxSmk + GxM	G + K + M + GxSmk + GxM	


BMI
Fat Percentage
HDL
Var Explained
1.00
0.75
0.50
0.25
0.00
GK
GKGxSmk
GKGxSmkxSex
Source
GxSmk
K
G


BMI
GS18K
G1
G2
G3
G4
Meta-analysis
G1
G2
G3
G4
Meta-analysis
G1
G2
G3
G4
Meta-analysis
GS
UKB
UKB_F
UKB_M
Cohort
0.0
0.1
0.2
0.3
Prop. of Trait Variance explained by GxSmoking


BMI
GS9K
Var Explained
1.00
0.75
0.50
0.25
0.00
GK
GKGxSmk
GKGxSmkxSex
GKM
GKMGxSmk
GKMGxM
GKMGxSmkGxM
GKMGxMxSex
Source
GxM
GxSmk
M
K
G